InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
13. Oktober 2021 08:30 ET
|
InspireMD Inc.
TEL AVIV, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery...
InspireMD Announces Strong Second Quarter 2021 Financial Results
10. August 2021 07:00 ET
|
InspireMD Inc.
Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET TEL AVIV, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc....
InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update
04. August 2021 08:30 ET
|
InspireMD Inc.
TEL AVIV, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
23. Juli 2021 08:30 ET
|
InspireMD Inc.
TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
02. Juni 2021 08:04 ET
|
InspireMD Inc.
TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery...
InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq
27. Mai 2021 08:00 ET
|
InspireMD Inc.
TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of...
InspireMD Commences Trading on Nasdaq-CM
21. Mai 2021 08:30 ET
|
InspireMD Inc.
TEL AVIV, Israel, May 21, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery...
InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021
14. Mai 2021 06:00 ET
|
InspireMD Inc.
TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
InspireMD Announces Appointment of Katie Arnold to Board of Directors
12. Mai 2021 06:00 ET
|
InspireMD Inc.
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces First Quarter 2021 Financial Results
11. Mai 2021 06:00 ET
|
InspireMD Inc.
Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021 Management to host investor conference call today, May 11, 2021, at 8:30am ET TEL AVIV, Israel,...